Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOTH6V)

Drug Name
Interferon alpha 2a Drug Info
Synonyms
LBSI-5535; Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV); Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV), LG Life Sciences; Sr-IFN alpha (Biohydrix sustained release/weekly dosing, HCV), LGLS
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMOTH6V

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon-alpha 2 (IFNA2) TTSIUJ9 IFNA2_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interferon-alpha 2 (IFNA2) DTT IFNA2 2.609 1.678 0.263 0.379
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hepatitis C virus infection
ICD Disease Classification 1E51.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interferon-alpha 2 (IFNA2) DTT IFNA2 9.31E-04 0.35 2.05
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000 Aug;18(16):2972-80.
2 Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60.